Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company's Clinical Program
Stock Information for Oncolytics Biotech Inc.
Loading
Please wait while we load your information from QuoteMedia.